Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Cancer Discov. 2018 Oct 29;9(2):230–247. doi: 10.1158/2159-8290.CD-18-0389

Figure 4: RB1 is synthetic lethal with AURKB in multiple SCLC and NSCLC cell lines.

Figure 4:

A, Immunoblot analysis of the indicated 3 RB1−/− SCLC cell lines and 3 EGFR-mutant RB1+/+ NSCLC cell lines. B, Growth inhibition (%), based on viable cell numbers relative to untreated controls, of the indicated cell lines treated with the AZD2811 for 72 hours. n=3 biological replicates. C, Immunoblot analysis of NCI-H82 cells infected with a lentivirus that constitutively expresses pRB or EV. D, Growth inhibition (%), based on viable cell numbers relative to untreated (DMSO) controls, of the cells in C, treated with the AZD2811 for 48 hours. n=3 biological replicates. *=p<0.05. E, Immunoblot analysis of NCI-H1975 RB1+/+ cells infected with a lentivirus that expresses Cas9 and an sgRNA targeting RB1 [or a non-targeting sgRNA (sgControl)]. F, Growth inhibition (%), based on viable cell numbers relative to untreated (DMSO) controls, of the cells in E, treated with the AZD2811 for 48 hours. n=4 biological replicates. *=p<0.05. G, Immunoblot analysis NCI-H1975 RB1+/+ cells that were first infected with a lentivirus that expresses Cas9 and an sgRNA targeting RB1 or a non-targeting sgRNA (sgControl) and then superinfected with an sgRNA targeting AURKB (sgAURKB) or a non-targeting sgRNA (sgControl) as indicated. H, Growth inhibition (%), based on viable cell numbers relative to sgControl cells in G, after growth in culture for 48 hours. n=2 biological replicates. *=p<0.05.